Is BPC-157 Legal in Arizona? How to Access It Through Legitimate Channels

What does federal status mean for Arizona?

No FDA-approved drug contains BPC-157, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. Arizona's pharmacy statute defines compounding as preparing a drug for dispensing to a patient based on a valid prescription order. The same definition also covers preparing drugs in anticipation of prescription orders and preparing drugs for administration by a medical practitioner to the practitioner's patient [7]. Compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before marketing [4].

Where BPC-157 sits in FDA's compounding framework

FDA tracks substances nominated for its pharmacy bulks list in three interim categories. BPC-157 is in none of them, so the category 1 enforcement-discretion policy does not cover it [2]. It was in category 2 (significant safety risks) from September 2023 until April 22, 2026, then moved to the nominated-but-withdrawn table after the groups that nominated it withdrew [5][4]. Removal was not a finding of safety. FDA's page still says compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and that FDA 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [5]. Outsourcing facilities have a separate list; BPC-157 is not on it either (updated March 21, 2025) [8].

What changed in 2026, and what did not

On July 23, 2026, the Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation [6][4]. That vote is advice only. BPC-157 is not on the list, and adding it requires formal rulemaking [6][4].

On October 28, 2026 HHS filed a notice announcing a draft enforcement-discretion policy for six peptides including BPC-157. It was scheduled for Federal Register publication on October 30, 2026, with public comments open for 2 weeks afterward [3][4]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the conditions are met [3][4]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue appears [3][4].

What this leaves for someone in Arizona

There is no approved BPC-157 product [1]. For an Arizona patient with a prescription, the October 2026 draft would require a state-licensed pharmacy to meet every condition:

• BPC-157 acetate only
• subcutaneous, intramuscular, oral or topical forms, with nasal, rectal and intravenous not listed
• a single active ingredient
• bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard
• the label reading 'This is a compounded drug product. Not for resale.'
• a patient-specific prescription
• serious adverse events and quality problems reported to FDA MedWatch
• only an FDA 510(k)-cleared syringe as a co-packaged device
• documentation of adequate bioavailability for oral forms [4]

The draft names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities, and BPC-157 is not on FDA's list for outsourcing facilities [4][8].